Health Therapies Clinics issues this advisory to patients and to the practitioners who hire rooms in our clinics.
Following a consultation earlier in 2026, the Therapeutic Goods Administration published an addendum to the permissible ingredients determination on 14 September 2026. It removed Andrographis from the ingredients permitted in listed medicines from 17 September 2026, citing allergy risk. On 21 September the TGA published guidance about action for listed medicines already on the market.
Metagenics ceased supply of all its products containing Andrographis at 5pm AEST on Friday 25 September 2026. The products are Metagenics Immune Active NK (item code IMA40) and Metagenics Gut InflamX (item code GIX60). The Healthy Market run by our clinic group sells Metagenics products to patients.
Practitioners using our rooms remain responsible for their own clinical decisions and should read the TGA material directly; Metagenics has asked practitioners to advise patients according to individual circumstances. Patients who have either product should speak with their practitioner, GP or pharmacist before continuing, and anyone with signs of an allergic reaction should seek medical help.
We will pass on further updates as the TGA and Metagenics publish them.
Patients with questions can raise them at their next consultation or call 0410 699 065.
Copyright© 2002-2026 visuallink© SaaS - Web Hosted Solutions, Design and Maintenance by Visual Link IT Pty Ltd - Software Solutions
Comments are disabled